Tvardi Therapeutics is trading 6.1% down at $1.24, amid broader biotech and macro pressure. - Shares declined 15.92% to $1.32 on September 23; no negative company-specific announcement was identified. - On September 24, the company reported constructive preclinical STAT3 data for ulcerative colitis. - Biotech is down 2.04%; rising Treasury yields and elevated oil prices are weighing on risk-sensitive growth stocks. The move remains active during regular trading.